載入中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$7.06
+US$0.25 · +3.67%
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
最新資料
US$7.06
+US$0.25 · +3.67%
盤中時間採用ET。市場資料可能有所延遲。
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
54
合理估值
情緒
51
多空交錯
風險
76
高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.43億 USD | 10.44億 USD | 10.49億 USD | 11.18億 USD | 17.74億 USD |
| 銷貨成本 | 3.92億 USD | 6.68億 USD | 6.89億 USD | 6.45億 USD | 9.8億 USD |
| 毛利 | 3.51億 USD | 3.75億 USD | 3.6億 USD | 4.73億 USD | 7.93億 USD |
| 研究與開發 | 5380萬 USD | 7070萬 USD | 1.11億 USD | 1.88億 USD | 2.35億 USD |
| 銷售、一般及管理費用 | 1.87億 USD | 2.99億 USD | 3.57億 USD | 3.4億 USD | 3.49億 USD |
| 營業費用 | 2.4億 USD | 4.84億 USD | 10.86億 USD | 6.43億 USD | 4.52億 USD |
| 利息支出 | 5930萬 USD | 7100萬 USD | 8790萬 USD | 3730萬 USD | 3450萬 USD |
| 折舊和攤銷 | 9580萬 USD | 1.09億 USD | 1.25億 USD | 1.43億 USD | 1.24億 USD |
| 營業利益 | 1.1億 USD | −1.09億 USD | −7.26億 USD | −1.7億 USD | 3.41億 USD |
| 淨利 | 5260萬 USD | −1.91億 USD | −7.61億 USD | −2.12億 USD | 2.2億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.00
上漲空間 41.64%報告持有此股票曝險的交易所交易基金。
Schwab International Equity ETFSCHF8033.88萬0.12%674.08億 USD0.03%US$27.27+0.66%
State Street SPDR Portfolio Developed World ex-US ETFSPDW5230.83萬0.13%404.62億 USD0.03%US$49.98+0.64%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ4214.96萬3.18%13億 USD0.48%US$35.59+0.57%
Schwab Fundamental International Large Company Index ETFFNDF2492.04萬0.10%253.2億 USD0.25%US$53.61+0.46%
Avantis U.S. Small Cap Value ETFAVUV2010.6萬0.06%308.51億 USD0.25%US$119.64-0.41%
State Street SPDR S&P Biotech ETFXBI1115.11萬0.11%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM962.14萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI948.01萬0.00%2.3兆 USD0.03%US$381.94+0.63%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQSchwab Fundamental International Large Company Index ETFFNDFAvantis U.S. Small Cap Value ETFAVUVState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
